1. Introduction {#sec1-medicina-55-00371}
===============

Disorders of sex development (DSD) is used as an umbrella term \[[@B1-medicina-55-00371]\] for various rare conditions that are characterized by an incongruence of chromosomal, gonadal, and genital sex development. XX male syndrome is part of DSD, so it is also called 46,XX testicular disorder of sex development. Patients generally have normal external genitalia and discover their pathology in adulthood because of infertility. Typical features of this condition are: 46,XX karyotype, normal male phenotype, small testes, azoospermia, and hypergonadotropic hypogonadism \[[@B2-medicina-55-00371]\].

It is a rare disease occurring in about 1:20,000 males \[[@B3-medicina-55-00371]\]. The first case was described in 1964 by De la Chapelle \[[@B4-medicina-55-00371]\]; since then, several other cases were reported. In this study we present the case report of a 36-year-old man suffering from XX male syndrome, presented as infertility, and perform a systematic review of the available evidences about the topic.

Case Report
-----------

A 36-year-old man came to our clinic complaining about infertility; he engaged in regular, unprotected sexual intercourse during the last 20 months without his wife becoming pregnant. His 30-year-old wife underwent a gynecological consultation and no remarkable diseases were diagnosed. He reported no familiar history of endocrine diseases, genetic syndromes or infertility and his medical history revealed only carpal tunnel release surgery; furthermore, no history of testicular trauma or cryptorchidism was present. The patient's job did not expose him to radiation or cytotoxic agents, and he did not take any medication. He had normal libido, good erectile function (International Index of Erectile Function (IIEF)-5 score: 22 points), normal morning erections, and no genital or urinary troubles. The patient complained of mild asthenia, impaired concentration, and breast growth in the last 2 years.

The height and weight of patient were 165 cm and 74 kg, respectively, with a BMI (body mass index) of 27.1 kg/m^2^), sagittal abdominal diameter of 29 cm, and his blood pressure was 110/70 mmHg. He presented sparse body hair and bilateral gynecomastia (grade II). The genital examination showed symmetrical male genitalia, stretched penis length of 8 cm, small testes (both 6 mL), and sparse pubic hair (Tanner stage II). No clinical varicocele was found. Digital rectal examination revealed a normal prostate gland. Standard abdominal ultrasound showed no significant disorders. Normal prostate gland and normal seminal vesicles, with no Müllerian derivates, were found with pelvic ultrasound. No varicocele was diagnosed with testicular ultrasound.

Hormone analysis revealed hypergonadotropic hypogonadism: follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were 24.7 mIU/mL (1--13 mIU/mL) and 9.4 mIU/mL (1--9 mIU/mL) respectively, whereas early morning total testosterone (TT) was 235 ng/dL (300--1200 ng/dL) and free testosterone (FT) calculated by formula was 3.5 pg/mL (9--30 pg/mL). Estradiol (E2) and prolactin (PRL) levels were 14 pg/mL (10--40 pg/mL) and 12.2 ng/mL (4--23 ng/mL) respectively, prostate-specific antigen (PSA) was 0.6 ng/mL, blood sugar was 88 mg/dL, total cholesterol was 213 mg/dL (\<200 mg/dL), hematocrit was 44% (41--50%) and hemoglobin was 15.4 g/dL (14--17.5 g/dL). The laboratory parameters were confirmed by a second dosage.

The semen analysis, according to the guidelines of the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen (5th edition), was performed after four days of abstinence and showed normal ejaculated volume (2.4 mL) and azoospermia after centrifugation. The semen collection was performed in the laboratory and it was analyzed within the following 30 min by two expert biologists. A second and a third sample confirmed similar values.

Karyotyping was performed on peripheral blood lymphocytes and showed a 46,XX karyotype. Fluorescent in situ hybridization (FISH) was carried out using the Vysis *SRY* probe revealing the sex-determining region Y (*SRY*) on the short (p) arm of the X chromosome. The patient underwent genetic consultation that confirmed the diagnosis of 46,XX (*SRY*-positive) DSD. A testicular biopsy was proposed to get a histological diagnosis, but the patient refused. Artificial insemination with sperm donation and psychological support were offered to the couple, and the patient is on clinical and laboratoristic follow-up.

2. Materials and Methods {#sec2-medicina-55-00371}
========================

2.1. Search Strategy {#sec2dot1-medicina-55-00371}
--------------------

We performed a systematic review of the available literature in September 2018, using MEDLINE, Web of Science, Embase, and Google Scholar database to search for all published studies regarding XX male syndrome. The following search terms were used: "46 XX male", "DSD", "infertility", "hypogonadism".

2.2. Inclusion and Exclusion Criteria {#sec2dot2-medicina-55-00371}
-------------------------------------

We included papers that met the following criteria: English language, human studies, adult patients (≥18 years old), full-text availability, completeness of clinical and laboratory data. No filters were applied for the date of publication.

Case reports of patients of pediatric age group and studies not having primary data (i.e., reviews not including case report, commentaries, and letters) were excluded, however they were examined to include any possible relevant citations.

2.3. Data Extraction {#sec2dot3-medicina-55-00371}
--------------------

Reference lists in relevant studies were used to search for additional studies. After a first screening based on study titles and abstracts, all selected papers were assessed based on the full-text to choose the relevant publications to be included in the analysis.

Two authors carried out this review independently (M.T., M.S.), and disagreements regarding the inclusion of some studies were resolved by discussion including all authors. An informed consent was obtained from the patient for the publication of the case report.

3. Results {#sec3-medicina-55-00371}
==========

3.1. Search Results {#sec3dot1-medicina-55-00371}
-------------------

The search strategy generated 160 papers. Screening of study titles and abstracts revealed 47 articles potentially eligible for inclusion; a further assessment based on the full-text led to the exclusion of 10 papers ([Figure 1](#medicina-55-00371-f001){ref-type="fig"}). The 37 selected studies described 64 adult patients with XX male syndrome \[[@B5-medicina-55-00371],[@B6-medicina-55-00371],[@B7-medicina-55-00371],[@B8-medicina-55-00371],[@B9-medicina-55-00371],[@B10-medicina-55-00371],[@B11-medicina-55-00371],[@B12-medicina-55-00371],[@B13-medicina-55-00371],[@B14-medicina-55-00371],[@B15-medicina-55-00371],[@B16-medicina-55-00371],[@B17-medicina-55-00371],[@B18-medicina-55-00371],[@B19-medicina-55-00371],[@B20-medicina-55-00371],[@B21-medicina-55-00371],[@B22-medicina-55-00371],[@B23-medicina-55-00371],[@B24-medicina-55-00371],[@B25-medicina-55-00371],[@B26-medicina-55-00371],[@B27-medicina-55-00371],[@B28-medicina-55-00371],[@B29-medicina-55-00371],[@B30-medicina-55-00371],[@B31-medicina-55-00371],[@B32-medicina-55-00371],[@B33-medicina-55-00371],[@B34-medicina-55-00371],[@B35-medicina-55-00371],[@B36-medicina-55-00371],[@B37-medicina-55-00371],[@B38-medicina-55-00371],[@B39-medicina-55-00371],[@B40-medicina-55-00371],[@B41-medicina-55-00371]\].

3.2. Synthesis of Results {#sec3dot2-medicina-55-00371}
-------------------------

The clinical data of the patients are summarized in [Table 1](#medicina-55-00371-t001){ref-type="table"}. Mean (SD) age was 33.14 (11.4) years, mean (SD) weight was 70.3 (10.2) kg and mean (SD) height was 165.3 (7.2) cm. Hair distribution was normal in 29/39 patients (74.3%), gynecomastia was absent in 22/39 cases (56.4%), normal testes volume was reported in 0/14 patients (in 50 patients this data was not available), penis size was normal in 26/32 cases (81.2%), pubic hair had a normal development in 6/7 patients (85.7%), normal erectile function was present in 27/30 cases (90%) and libido was preserved in 20/20 patients (100%).

The hormone profile of the patients is reported in [Table 2](#medicina-55-00371-t002){ref-type="table"}. The data revealed the common presence of hypergonadotropic hypogonadism. Mean (SD) FSH was 40.00 (19.7) mIU/mL, mean (SD) LH was 26.5 (16.7) mIU/mL and mean (SD) total testosterone was 2.6 (1.4) ng/mL.

The genetic features of the patients are listed in [Table 3](#medicina-55-00371-t003){ref-type="table"}. All patients had a 46,XX karyotype. The *SRY* gene was detected in 51/57 cases (89.5%) and was absent in 6/57 (10.5%) cases. It was not described in the case reports of four patients. The position of the *SRY* was on the Xp in 97% of the cases.

The patients were stratified by *SRY* into two groups: *SRY*-positive (*SRY*+) and *SRY*-negative (*SRY*--). A statistical analysis was performed in order to find significant clinical or hormonal differences between the two groups ([Table 4](#medicina-55-00371-t004){ref-type="table"}).

Hair distribution, gynecomastia, testes volume, penis size, pubic hair, erectile dysfunction, libido, FSH, LH, PRL, and E2 were compared: no statistically significant differences (*p* \> 0.05) were found between the *SRY*-positive and *SRY*-negative patients for comparable parameters. However, it was not possible to compare all parameters between the two groups because there were few *SRY-negative* cases and limited available data.

4. Discussion {#sec4-medicina-55-00371}
=============

The term DSD, introduced by the Chicago Consensus Group in 2005, distinguishes three major groups:DSD with atypical sex chromosome configurations, including Turner syndrome, Klinefelter syndrome, and conditions with 46,XX or 46,XY karyotypes;XY DSD characterized by 46,XY karyotype;XX DSD comprised of conditions characterized by 46,XX karyotype and androgen excess, such as congenital adrenal hyperplasia, P450 oxidoreductase deficiency, or exogenous causes \[[@B42-medicina-55-00371]\].

Male adults with 46,XX and DSD are part of the first of these three groups. Many patients with 46,XX karyotype have external male genitalia \[[@B11-medicina-55-00371]\], but they generally have small testes and may also have abnormalities such as cryptorchidism or hypospadias, azoospermia, hypergonadotropic hypogonadism, varying degrees of gynecomastia, poor facial hair growth, diminished libido, and normal cognitive development \[[@B43-medicina-55-00371]\]. No extra-genital abnormalities were found in all reported cases. However, phenotypes in these patients were different, ranging from severe impairment of the external genitalia to hypospadias and/or cryptorchidism to normal male phenotype. It depends mainly, but not only, on the presence of the sex-determining region Y (*SRY*). In recent years a number of other genes involved in disorders of sex development have also been identified. For instance, *SOX9*, *SOX3*, *DAX1*, *WT1*, *FGF9*, and *SF1* are also involved in the sex determination cascade \[[@B44-medicina-55-00371],[@B45-medicina-55-00371]\]. Therefore, taking the *SRY* gene as the only target gene \[[@B3-medicina-55-00371]\] may not provide enough information, and the clinical manifestations of some of the 46,XX male patients were not consistent with the expression of the *SRY* gene. Regardless, male sex differentiation is mostly dependent on the presence of the *SRY* gene, which drives the primitive gonads into testes formation during early human embryonic development \[[@B46-medicina-55-00371]\]. This belief is held because XX *SRY*+ subjects are generally men with male genitalia, whereas XX *SRY*− subjects have ambiguous genitalia. Nevertheless, there are a few XX *SRY*+ subjects with ambiguous sexual characteristics and, therefore, another Y chromosome gene contributing to complete male sex differentiation has been postulated. In a small number of *SRY*+ cases with ambiguous genitalia, there is a small Y fragment located on inactive X in most metaphases \[[@B47-medicina-55-00371],[@B48-medicina-55-00371]\]. Kolon \[[@B44-medicina-55-00371]\] reports that, in general, the greater the amount of Y chromosome DNA present, the more masculinized the phenotype will be. Male adults with 46,XX and normal external genitalia generally discover their pathology in adulthood because of infertility. Infertility affects approximately 10--15% of all couples worldwide \[[@B8-medicina-55-00371]\]. Approximately 30--40% of infertility cases can be attributed to male factors \[[@B49-medicina-55-00371]\]. In about 15% of male infertility cases, no organic cause can be identified \[[@B8-medicina-55-00371]\]. Idiopathic infertility found in most cases of non-obstructive azoospermia (NOA) or severe oligozoospermia is due to chromosomal abnormalities or mutations of genes involved in sex determination and spermatogenesis \[[@B50-medicina-55-00371]\]. The incidence of cytogenetic abnormality is estimated at 5.8% in infertile men and only 0.5% in the normal population \[[@B51-medicina-55-00371]\].

Diagnosis is based on clinical findings, endocrine testing, and cytogenetic testing \[[@B2-medicina-55-00371]\]. Cryptorchidism is present in 15% and anterior hypospadias in around 10%. Endocrine testing normally reveals hypergonadotropic hypogonadism secondary to testicular failure \[[@B2-medicina-55-00371],[@B47-medicina-55-00371]\]. Cytogenetic testing reveals 46,XX. Approximately 80% of 46,XX DSD individuals are *SRY*+, and around 20% are *SRY*− \[[@B2-medicina-55-00371],[@B47-medicina-55-00371]\]. The investigation is usually based on fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) amplification of the *SRY* gene.

There is no literature regarding the comparison between FISH and PCR for *SRY* detection and location. Considering similar studies were performed in different contexts (e.g., detection of *BCR-ABL* fusion gene, detection of translocation *RCC*), we think that FISH and RT-PCR should be used together in order to improve the sensitivity of *SRY* detection and location \[[@B42-medicina-55-00371],[@B52-medicina-55-00371]\].

Various studies indicated that 80--90% of 46,XX males result from a Y to X translocation during meiosis \[[@B49-medicina-55-00371],[@B53-medicina-55-00371]\]. 46,XX males who showed no evidence of Y specific DNA, including *SRY*, were reported \[[@B50-medicina-55-00371]\]. This suggests that testicular development in these males occurred in the absence of the *SRY* gene. On the basis of karyotype analysis and detection of the *SRY* gene, 46,XX male patients can be clinically divided \[[@B3-medicina-55-00371]\] into the *SRY*-positive and the *SRY*-negative groups.

The *SRY* gene is identified as the main gene regulating the testes determination cascade. The most important role of *SRY* is to regulate the *SOX9* expression in Sertoli cell precursors. This pathway, in turn, activates testis-specific genes leading to testis determination \[[@B51-medicina-55-00371]\].

In the absence of *SRY* (*SRY*-negative patients), the male phenotype develops probably from the gain of function in a gene downstream to the *SRY* pathway \[[@B29-medicina-55-00371]\]. *SOX9*, *SOX3*, *DAX1*, *WT1*, *FGF9*, and *SF1* are also involved in the sex determination cascade \[[@B54-medicina-55-00371]\]. While the clinical symptoms of patients often show some degree of heterogeneity \[[@B55-medicina-55-00371]\], usually, the development of genitalia is normal and masculinity signs are obvious in *SRY*+ patients. There is no abnormality in the development of penis and sex psychology as well as erection and ejaculation, and there are almost no significant positive signs except cryptorchidism before puberty. So, it is difficult to find SRY+ male DSD patients before puberty, who are often incidentally found by chromosome check for infertility or poor testicle development. On the contrary, *SRY*− patients could be easily discriminated due to abnormality of genitalia shortly after birth; some patients even show genital ambiguity \[[@B55-medicina-55-00371]\]. Masculinity signs are not clear in *SRY*− patients; especially in adult patients. Breast development and female secondary sex characteristics can be found. For patients with the *SRY*− gene, due to genital ambiguity, patients' sex psychology and physiological development should be carefully taken into consideration for treatment \[[@B3-medicina-55-00371]\] and the patient may not be able to avoid drug-dependence for maintaining the secondary sex characteristics.

On the basis of our statistical analysis the presence/absence of *SRY* does not seem to affect the clinical and hormonal characteristics of the patients, however the *SRY*− cases are fewer than the *SRY*+ cases. This may have erroneously led to a no statistically significant difference between the two groups.

Individuals with the 46,XX male syndrome may have phenotypic and endocrinologic status that would be expected to be the same as in Klinefelter's syndrome characterized by 47,XXY. Thus, this syndrome is considered as a variant form of Klinefelter's syndrome. However, one does not always assume that a 46,XX male will be similar to individuals with Klinefelter's syndrome \[[@B13-medicina-55-00371]\], which has the characteristics of tall stature, gynecomastia, small testicular volume, a borderline-low intelligence quotient (IQ), and hypergonadotropic hypogonadism. Some 46,XX males do not have gynecomastia, hypogonadism, or even exaggerated LH-releasing hormone (LHRH)-stimulated gonadotropin response \[[@B56-medicina-55-00371]\]. In 46,XX male syndrome, different from Klinefelter's syndrome, there is short stature which is probably due to translocations of sex chromosomes or to genetic defects that affect growth hormone (GH) activity. Chung-Jung et al. \[[@B13-medicina-55-00371]\] found exaggerated GH response after an insulin-induced hypoglycemic test. They suggested that the short stature in patients with 46,XX male syndrome should not be attributed to the syndrome itself. They speculate possible defects of GH activity as in partial GH insensitivity syndrome that involves genes controlling expression of GH receptor. Anyway, the pathogenesis of 46,XX male DSD is not clear. According to Wang et al. \[[@B3-medicina-55-00371]\], the hypotheses are as follows:The hypothesis of target gene mutation \[[@B57-medicina-55-00371]\]. It supposes the structural gene that determines human gender may be located in autosome, which is regulated by the inhibition of the X chromosome and the activation of the Y chromosome. 46,XX individuals, due to defects in the inhibition of the X chromosome, which results in spontaneous activation of the downstream gene in the absence of the *SRY* gene, transform into 46,XX males.The hypothesis of *SOX9* gene (*SRY* box-related gene 9) overexpression. *SOX* are a large gene family, in which *SOX9* is located in 17q24.3--q25.1 and homologous with *SRY* High-Mobility Group box (HMG)-box as high as 60%. Early studies confirmed that *SOX9* was mainly involved in bone formation and the regulation of Sertoli cell differentiation \[[@B58-medicina-55-00371]\], which was also expressed in the precursor cell of supporting cells with the *SRY* gene expression. In addition, the fact that *SOX9* can be found in spinal animals and mammals, compared with the *SRY* gene which can be found only in mammals, might indicate that *SOX9* was a more ancient gene involved in sex differentiation than the *SRY* gene. Huang et al. \[[@B59-medicina-55-00371]\] reported the case of a *SRY*-negative 46,XX male patient, and chromosome analysis showed the existence of overlapping of the *SOX9* gene. Malki et al. \[[@B60-medicina-55-00371]\] found that prostaglandin D2 (PGD2) could induce the expression of *SOX9* in a normal female rat gonad in vitro. Thus, up-regulation of *SOX9* expression caused by chromosomal abnormalities or mediated by other bypass activation (e.g., PGD2) may result in the occurrence of *SRY*-negative 46,XX male patients.The hypothesis of Xp-Yp translocation. It supposes that the ends of the XY chromosomes' abnormal exchange (Xp-Yp translocation) occurs during paternal sperm meiosis and results in X-type sperm containing the *SRY* gene, which could lead to 46,XX offspring when combined with eggs. PCR can detect the *SRY* gene, however, only to find it translocated in the X chromosome by FISH. In Brazil, Domenice et al. \[[@B61-medicina-55-00371]\] found that 90% of 46,XX males carried Y chromosome material, including the *SRY* gene, in most cases. It indicated that the Y chromosome fragment containing the *SRY* gene translocation may be an important factor for the occurrence of *SRY*+ 46,XX male patients.

Facing a patient with 46,XX male syndrome, the clinician should keep in mind the possible abnormalities linked to the syndrome and thus perform an adequate screening: an appropriate physical examination should include evaluation and palpation of the genitalia to detect cryptorchidism, hypospadias, penis size, and gynecomastia. It is important to use a validated questionnaire to evaluate erectile dysfunction and diminished libido, such as the International Index of Erectile Function (IIEF); semen analysis is mandatory (even though this is often the reason why they come to the urologist) and so is the karyotype test. An abdominal ultrasound is useful in order to exclude residual Müllerian structures. Genetic and endocrine consultations are necessary to assess the status of the patient who often has hypergonadotropic hypogonadism ([Figure 2](#medicina-55-00371-f002){ref-type="fig"}).

In *SRY*-negative patients, no further instrumental or blood tests are necessary, however, we suggest searching for mutations of other genes involved in the sex determination cascade such as *SOX9*, *SOX3*, *DAX1*, *WT1*, *FGF9*, and *SF1*.

5. Conclusions {#sec5-medicina-55-00371}
==============

In conclusion, 46,XX male DSD, characterized by mismatch of genetic, gonadal, and phenotypic sex is quite rare, and due to genetic or chromosomal abnormalities. FISH and PCR technology can quickly and accurately detect information about the *SRY* gene in patients, so as to provide more valuable clinical information. Although chromosomal abnormalities are rarely present in patients with apparently normal external genitalia, they should be considered in urology consultations by adolescents and adults, particularly in the investigation of gynecomastia or infertility. Finally, considering genetic abnormalities, testicular sperm extraction (TESE) is not recommended and these patients should consider adoption or in vitro fertilization with a sperm donor as fertility options.
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medicina-55-00371-t001_Table 1

###### 

Clinical data of 46, XX male adults.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                          Age\    Weight\   Height\   HD       GM    Testes Volume   Penis Size   Pubic Hair   ED    Libido
                                                   Years   kg        cm                                                                       
  ------------------------------------------------ ------- --------- --------- -------- ----- --------------- ------------ ------------ ----- --------
  Guzman et al. \[[@B5-medicina-55-00371]\]        20      76        169       Normal   No    Small           Normal       Normal       No    Normal

  Gunes et al. \[[@B6-medicina-55-00371]\]         30      70        155       Poor     Yes   Small           Normal       Normal       No    Normal

  Gunes et al. \[[@B6-medicina-55-00371]\]         16      65        152       Normal   No    Small           Normal       Normal       No    Normal

  Valetto et al. \[[@B7-medicina-55-00371]\]       35      48        152       Normal   No    NA              Normal       NA           No    Normal

  Kim et al. \[[@B8-medicina-55-00371]\]           29      62        165       Normal   No    NA              NA           NA           Yes   NA

  Xiao et al. \[[@B9-medicina-55-00371]\]          27      NA        170       NA       NA    NA              Small        NA           No    NA

  Queralt et al. \[[@B10-medicina-55-00371]\]      31      58        170       Normal   No    NA              NA           NA           NA    NA

  Baziz et al. \[[@B11-medicina-55-00371]\]        44      NA        NA        Normal   Yes   Small           Normal       NA           No    Normal

  Tomomasa et al. \[[@B12-medicina-55-00371]\]     25      55        177       Normal   No    Small           NA           Normal       NA    Normal

  Chung Jung et al. \[[@B13-medicina-55-00371]\]   17      NA        154       Normal   No    Small           Normal       Normal       No    Normal

  Wang et al. \[[@B14-medicina-55-00371]\]         20      NA        NA        Poor     No    Small           Normal       Inverted     No    Normal

  Ahsan T et al. \[[@B15-medicina-55-00371]\]      24      NA        NA        Poor     Yes   Small           Normal       Normal       No    Normal

  Jain et al. \[[@B16-medicina-55-00371]\]         38      63        162       Normal   Yes   NA              Normal       NA           Yes   NA

  Yencilek et al. \[[@B17-medicina-55-00371]\]     26      72        165       Normal   No    NA              Small        NA           No    NA

  Pepene et al. \[[@B18-medicina-55-00371]\]       28      65        167       Normal   Yes   Small           Normal       NA           No    Normal

  Mustafa et al. \[[@B19-medicina-55-00371]\]      30      75        170       Normal   Yes   NA              Normal       NA           NA    Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      40      84        175       Normal   No    NA              Normal       NA           No    Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      31      NA        NA        Normal   No    NA              Normal       NA           No    Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      35      NA        NA        Poor     Yes   NA              Normal       NA           Yes   Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      39      74        160       Normal   No    Small           Normal       NA           No    Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      29      77        181       Normal   No    NA              Normal       NA           No    Normal

  Majzoub et al. \[[@B20-medicina-55-00371]\]      32      86        170       Normal   Yes   NA              Normal       NA           No    Normal

  Onrat et al. \[[@B21-medicina-55-00371]\]        23      NA        NA        Normal   No    Small           Normal       NA           No    Normal

  Hado et al. \[[@B22-medicina-55-00371]\]         76      NA        157       Normal   Yes   NA              NA           NA           No    Normal

  Rigola et al. \[[@B23-medicina-55-00371]\]       33      NA        NA        Normal   No    NA              Normal       NA           NA    NA

  Dauwerse et al. \[[@B24-medicina-55-00371]\]     61      NA        171       NA       No    Small           Normal       NA           NA    NA

  Ryan et al. \[[@B25-medicina-55-00371]\]         40      NA        NA        Poor     No    NA              3.6          NA           No    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        163       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        163       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        162       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        161       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        158       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        162       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        162       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        161       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        160       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        160       NA       NA    NA              NA           NA           NA    NA

  Gao et al. \[[@B26-medicina-55-00371]\]          NA      NA        161       NA       NA    NA              NA           NA           NA    NA

  Rizvi et al. \[[@B27-medicina-55-00371]\]        33      85.8      177       NA       NA    NA              Normal       NA           No    NA

  Minor et al. \[[@B28-medicina-55-00371]\]        24      NA        NA        NA       Yes   NA              NA           NA           NA    NA

  Rajender et al. \[[@B29-medicina-55-00371]\]     34      64        156       Normal   No    NA              Normal       NA           NA    NA

  Tan et al. \[[@B30-medicina-55-00371]\]          NA      NA        176       Normal   Yes   NA              Small        NA           No    NA

  Zakharia et al. \[[@B31-medicina-55-00371]\]     65      65        165       NA       Yes   NA              Normal       NA           No    NA

  Chiang et al. \[[@B32-medicina-55-00371]\]       33      NA        NA        NA       NA    NA              NA           NA           No    NA

  Chiang et al. \[[@B32-medicina-55-00371]\]       34      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Chiang et al. \[[@B32-medicina-55-00371]\]       52      NA        NA        NA       NA    NA              Small        NA           NA    NA

  Wu et al. \[[@B33-medicina-55-00371]\]           NA      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Wu et al. \[[@B33-medicina-55-00371]\]           NA      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Wu et al. \[[@B33-medicina-55-00371]\]           NA      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Wu et al. \[[@B33-medicina-55-00371]\]           NA      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Wu et al. \[[@B33-medicina-55-00371]\]           NA      NA        NA        NA       NA    NA              NA           NA           NA    NA

  Chernykh et al. \[[@B34-medicina-55-00371]\]     37      74        160       Poor     Yes   NA              NA           NA           NA    NA

  Butler et al. \[[@B35-medicina-55-00371]\]       31      72        169       Normal   Yes   NA              Normal       NA           No    NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   28      NA        180       Normal   Yes   NA              NA           NA           NA    NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   35      NA        170       Normal   NA    Small           NA           NA           NA    NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   28      NA        160       Poor     NA    NA              NA           NA           NA    NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   39      NA        174       Poor     NA    NA              NA           NA           NA    NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   24      NA        172       Normal   NA    NA              NA           NA           NA    NA

  Fuse et al. \[[@B37-medicina-55-00371]\]         30      90        172       Normal   No    NA              NA           NA           NA    NA

  Pais et al. \[[@B38-medicina-55-00371]\]         29      82        170       Normal   Yes   NA              Small        NA           No    NA

  Wegner et al. \[[@B39-medicina-55-00371]\]       35      81        167       Normal   No    NA              Normal       NA           NA    NA

  Micic et al. \[[@B40-medicina-55-00371]\]        25      63        171       Poor     No    NA              NA           NA           No    NA

  Matthews et al. \[[@B41-medicina-55-00371]\]     27      68        166       Poor     No    NA              NA           NA                 NA

  Our case                                         36      74        165       NA       Yes   Small           Normal       NA           No    Normal
  ----------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available; HD: hair distribution; GM: gynecomastia; ED: erectile disfunction.

medicina-55-00371-t002_Table 2

###### 

Hormone profile of 46,XX male adults.

  ------------------------------------------------------------------------------------------
  Authors                                          FSH\     LH\      TT\     E2\     PRL\
                                                   mIU/mL   mIU/mL   ng/mL   pg/mL   ng/mL
  ------------------------------------------------ -------- -------- ------- ------- -------
  Guzman et al. \[[@B5-medicina-55-00371]\]        27.9     16.5     2.3     24.8    24.5

  Gunes et al. \[[@B6-medicina-55-00371]\]         37.88    18.96    0.51    17.57   17.54

  Gunes et al. \[[@B6-medicina-55-00371]\]         41.05    14.55    2.16    32      24.11

  Valetto et al. \[[@B7-medicina-55-00371]\]       23.9     17.7     3.06    NA      7.13

  Kim et al. \[[@B8-medicina-55-00371]\]           76       41       1.79    NA      NA

  Xiao et al. \[[@B9-medicina-55-00371]\]          47       18.7     1.80    NA      14.6

  Queralt et al. \[[@B10-medicina-55-00371]\]      62.2     25.8     3.23    17      NA

  Baziz et al. \[[@B11-medicina-55-00371]\]        51       11.71    NA      NA      NA

  Tomomasa et al. \[[@B12-medicina-55-00371]\]     19.7     10.3     4.28    NA      NA

  Chung Jung et al. \[[@B13-medicina-55-00371]\]   25.1     11.4     4.3     30.1    16.8

  Wang et al. \[[@B14-medicina-55-00371]\]         77.5     40.75    4.64    NA      15.59

  Ahsan T et al. \[[@B15-medicina-55-00371]\]      35       21       1.8     NA      NA

  Jain et al. \[[@B16-medicina-55-00371]\]         76.6     36.3     1.20    NA      NA

  Yencilek et al. \[[@B17-medicina-55-00371]\]     45.6     48.9     2.70    NA      9.4

  Pepene et al. \[[@B18-medicina-55-00371]\]       43.9     25.3     3.33    NA      NA

  Mustafa et al. \[[@B19-medicina-55-00371]\]      NA       40.7     2.11    16.6    8.5

  Majzoub et al. \[[@B20-medicina-55-00371]\]      38       12       3.35    29      13.6

  Majzoub et al. \[[@B20-medicina-55-00371]\]      14       6        1.29    25      3.2

  Majzoub et al. \[[@B20-medicina-55-00371]\]      10       23       0.74    5.7     NA

  Majzoub et al. \[[@B20-medicina-55-00371]\]      28       15       0.74    NA      NA

  Majzoub et al. \[[@B20-medicina-55-00371]\]      13.4     12       2.46    19      NA

  Majzoub et al. \[[@B20-medicina-55-00371]\]      29.7     16.9     0.95    NA      12

  Onrat et al. \[[@B21-medicina-55-00371]\]        9.95     17.3     0.20    NA      NA

  Hado et al. \[[@B22-medicina-55-00371]\]         27.8     21       2.59    NA      NA

  Rigola et al. \[[@B23-medicina-55-00371]\]       NA       NA       NA      NA      NA

  Dauwerse et al. \[[@B24-medicina-55-00371]\]     13       10       3.25    31.3    NA

  Ryan et al. \[[@B25-medicina-55-00371]\]         1        NA       NA      10      NA

  Gao et al. \[[@B26-medicina-55-00371]\]          93.6     19.4     3.08    33      17.9

  Gao et al. \[[@B26-medicina-55-00371]\]          24.7     14.4     2.77    43      18.5

  Gao et al. \[[@B26-medicina-55-00371]\]          NA       NA       1.29    NA      NA

  Gao et al. \[[@B26-medicina-55-00371]\]          81.6     27.7     1.37    19.8    22.9

  Gao et al. \[[@B26-medicina-55-00371]\]          13.1     3.61     2.44    34      9.67

  Gao et al. \[[@B26-medicina-55-00371]\]          54.7     19.4     1.72    27      10.08

  Gao et al. \[[@B26-medicina-55-00371]\]          37.1     16.5     3.19    28      9.88

  Gao et al. \[[@B26-medicina-55-00371]\]          43       33.9     2.16    22      7.28

  Gao et al. \[[@B26-medicina-55-00371]\]          72       34.6     3.36    19.8    10

  Gao et al. \[[@B26-medicina-55-00371]\]          49       26.8     1.80    19.8    15.8

  Gao et al. \[[@B26-medicina-55-00371]\]          87.7     31.4     5.21    30.5    49.6

  Rizvi et al. \[[@B27-medicina-55-00371]\]        46       23       2.07    NA      NA

  Minor et al. \[[@B28-medicina-55-00371]\]        55.4     28.4     0.119   NA      NA

  Rajender et al. \[[@B29-medicina-55-00371]\]     25.8     15.8     5.8     NA      NA

  Tan et al. \[[@B30-medicina-55-00371]\]          21       34       2.63    25      NA

  Zakharia et al. \[[@B31-medicina-55-00371]\]     72       61       2.40    NA      16.3

  Chiang et al. \[[@B32-medicina-55-00371]\]       46.5     17.6     2.03    NA      27.05

  Chiang et al. \[[@B32-medicina-55-00371]\]       54.3     19.6     2.17    NA      8.15

  Chiang et al. \[[@B32-medicina-55-00371]\]       64.3     20.2     1.44    NA      16.08

  Wu et al. \[[@B33-medicina-55-00371]\]           35.5     13.8     1.95    30.5    4.6

  Wu et al. \[[@B33-medicina-55-00371]\]           29.2     12.9     1.55    19.1    3.6

  Wu et al. \[[@B33-medicina-55-00371]\]           45.9     25.1     2.56    26.7    7.8

  Wu et al. \[[@B33-medicina-55-00371]\]           33.7     22.3     2.41    29.1    10.9

  Wu et al. \[[@B33-medicina-55-00371]\]           31.4     19.6     2.01    22.1    7.8

  Chernykh et al. \[[@B34-medicina-55-00371]\]     26.9     13.5     2.90    NA      NA

  Butler et al. \[[@B35-medicina-55-00371]\]       51       NA       4.77    NA      NA

  Castineyra et al. \[[@B36-medicina-55-00371]\]   50       16       3.00    28      14

  Castineyra et al. \[[@B36-medicina-55-00371]\]   3.5      6.2      7.00    38      3.4

  Castineyra et al. \[[@B36-medicina-55-00371]\]   21       5.2      1.40    19      8.1

  Castineyra et al. \[[@B36-medicina-55-00371]\]   6.7      4.2      5.60    30      6.2

  Castineyra et al. \[[@B36-medicina-55-00371]\]   45       40       3.00    20      5.4

  Fuse et al. \[[@B37-medicina-55-00371]\]         47       60       1.60    NA      NA

  Pais et al. \[[@B38-medicina-55-00371]\]         53       45       2.67    NA      NA

  Wegner et al. \[[@B39-medicina-55-00371]\]       23.7     37.1     6.30    NA      3.8

  Micic et al. \[[@B40-medicina-55-00371]\]        31       18       3.19    47      6.8

  Matthews et al. \[[@B41-medicina-55-00371]\]     46       19       2.82    33      9.87

  Our case                                         24.7     9.4      2.7     14      12.2
  ------------------------------------------------------------------------------------------

NA: not available; FSH: follicle-stimulating hormone; LH: luteinizing hormone; TT: total testosterone; E2: estradiol; PRL: prolactin.

medicina-55-00371-t003_Table 3

###### 

Genetic features of 46,XX male adults.

  Authors                                          Presence of *SRY*   Location of *SRY*
  ------------------------------------------------ ------------------- -------------------
  Guzman et al. \[[@B5-medicina-55-00371]\]        \+                  NA
  Gunes et al. \[[@B6-medicina-55-00371]\]         \+                  NA
  Gunes et al. \[[@B6-medicina-55-00371]\]         \+                  NA
  Valetto et al. \[[@B7-medicina-55-00371]\]       NA                  NA
  Kim et al. \[[@B8-medicina-55-00371]\]           NA                  NA
  Xiao et al. \[[@B9-medicina-55-00371]\]          −                   NA
  Queralt et al. \[[@B10-medicina-55-00371]\]      \+                  NA
  Baziz et al. \[[@B11-medicina-55-00371]\]        \+                  NA
  Tomomasa et al. \[[@B12-medicina-55-00371]\]     \+                  NA
  Chung Jung et al. \[[@B13-medicina-55-00371]\]   \+                  NA
  Wang et al. \[[@B14-medicina-55-00371]\]         \+                  NA
  Ahsan T et al. \[[@B15-medicina-55-00371]\]      NA                  NA
  Jain et al. \[[@B16-medicina-55-00371]\]         \+                  NA
  Yencilek et al. \[[@B17-medicina-55-00371]\]     NA                  NA
  Pepene et al. \[[@B18-medicina-55-00371]\]       \+                  NA
  Mustafa et al. \[[@B19-medicina-55-00371]\]      −                   NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      \+                  NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      \+                  NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      \+                  NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      −                   NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      \+                  NA
  Majzoub et al. \[[@B20-medicina-55-00371]\]      \+                  NA
  Onrat et al. \[[@B21-medicina-55-00371]\]        \+                  NA
  Hado et al. \[[@B22-medicina-55-00371]\]         \+                  NA
  Rigola et al. \[[@B23-medicina-55-00371]\]       \+                  Xp
  Dauwerse et al. \[[@B24-medicina-55-00371]\]     \+                  16q
  Ryan et al. \[[@B25-medicina-55-00371]\]         −                   NA
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Gao et al. \[[@B26-medicina-55-00371]\]          \+                  Xp
  Rizvi et al. \[[@B27-medicina-55-00371]\]        \+                  Xp
  Minor et al. \[[@B28-medicina-55-00371]\]        \+                  Xp
  Rajender et al. \[[@B29-medicina-55-00371]\]     −                   NA
  Tan et al. \[[@B30-medicina-55-00371]\]          NA                  NA
  Zakharia et al. \[[@B31-medicina-55-00371]\]     NA                  NA
  Chiang et al. \[[@B32-medicina-55-00371]\]       \+                  Xp
  Chiang et al. \[[@B32-medicina-55-00371]\]       \+                  Xp
  Chiang et al. \[[@B32-medicina-55-00371]\]       −                   NA
  Wu et al. \[[@B33-medicina-55-00371]\]           \+                  Xp
  Wu et al. \[[@B33-medicina-55-00371]\]           \+                  Xp
  Wu et al. \[[@B33-medicina-55-00371]\]           \+                  Xp
  Wu et al. \[[@B33-medicina-55-00371]\]           \+                  Xp
  Wu et al. \[[@B33-medicina-55-00371]\]           \+                  Xp
  Chernykh et al. \[[@B34-medicina-55-00371]\]     \+                  Xp
  Butler et al. \[[@B35-medicina-55-00371]\]       \+                  Xp
  Castineyra et al. \[[@B36-medicina-55-00371]\]   \+                  Xp
  Castineyra et al. \[[@B36-medicina-55-00371]\]   \+                  Xp
  Castineyra et al. \[[@B36-medicina-55-00371]\]   \+                  Xp
  Castineyra et al. \[[@B36-medicina-55-00371]\]   \+                  Xp
  Castineyra et al. \[[@B36-medicina-55-00371]\]   \+                  Xp
  Fuse et al. \[[@B37-medicina-55-00371]\]         \+                  Xp
  Pais et al. \[[@B38-medicina-55-00371]\]         \+                  Xp
  Wegner et al. \[[@B39-medicina-55-00371]\]       \+                  Xp
  Micic et al. \[[@B40-medicina-55-00371]\]        NA                  NA
  Matthews et al. \[[@B41-medicina-55-00371]\]     \+                  Xp
  Our case                                         \+                  Xp

NA: not available; *SRY*: sex-determining region Y; Xp: short arm of X chromosome.

medicina-55-00371-t004_Table 4

###### 

Comparison of *SRY*-positive and *SRY*-negative patients.

  --------------------------------------------------------------------------------------------------------------------------------------
  Patients   HD% Normal    GM% No        Penis size% Normal   ED% No        FSH\            LH\             TT\           PRL\
                                                                            mIU/mL\         mIU/mL\         ng/mL\        ng/mL\
                                                                            Mean (SD)       Mean (SD)       Mean (SD)     Mean (SD)
  ---------- ------------- ------------- -------------------- ------------- --------------- --------------- ------------- --------------
  *SRY*+     73.3          55.2          90.9                 90.0          38.63 (20.85)   29.40 (19.09)   2.64 (1.49)   12.93 (9.32)

  *SRY*−     66.7          57.1          60.0                 85.7          51.74 (28.14)   21.63 (9.56)    2.49 (1.79)   14.27 (4.07)

             *p =* 0.422   *p =* 0.596   *p =* 0.144          *p =* 0.823   *p =* 0.195     *p =* 0.326     *p =* 0.819   *p =* 0.781
  --------------------------------------------------------------------------------------------------------------------------------------

HD: hair distribution; GM: gynecomastia; ED: erectile disfunction; FSH: follicle-stimulating hormone; LH: luteinizing hormone; TT: total testosterone; PRL: prolactin.
